Compare DLNG & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DLNG | ATRA |
|---|---|---|
| Founded | 2013 | 2012 |
| Country | Greece | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.0M | 129.4M |
| IPO Year | 2013 | 2014 |
| Metric | DLNG | ATRA |
|---|---|---|
| Price | $3.87 | $4.55 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 54.7K | ★ 610.3K |
| Earning Date | 03-05-2026 | 03-06-2026 |
| Dividend Yield | ★ 5.14% | N/A |
| EPS Growth | ★ 30.14 | N/A |
| EPS | 1.29 | ★ 1.97 |
| Revenue | ★ $158,275,000.00 | $151,930,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $0.37 | N/A |
| P/E Ratio | $3.02 | ★ $2.31 |
| Revenue Growth | 4.34 | ★ 51.27 |
| 52 Week Low | $3.18 | $4.25 |
| 52 Week High | $5.35 | $19.15 |
| Indicator | DLNG | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 60.55 | 23.81 |
| Support Level | $3.70 | $4.25 |
| Resistance Level | $4.18 | $5.19 |
| Average True Range (ATR) | 0.13 | 1.63 |
| MACD | 0.01 | -1.54 |
| Stochastic Oscillator | 50.00 | 2.07 |
Dynagas LNG Partners LP is a limited partnership company focused on owning and operating high specification and versatile LNG carriers that are employed on multi-year contracts with international energy companies, providing the benefits of stable cash flows and high utilization rates. The company defines charters of two years or more as multi-year charters. Its current LNG Carrier fleet is optimized for trading flexibility. In addition to conventional trade, part of LNG Carrier fleet is assigned with Ice Class 1A FS notation and are winterized which enables trade in subzero and ice bound conditions.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).